Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.

Curr HIV Res · 2013 · PMC3871422 · PMID 23590675

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

In the CASTLE study (31% of women at baseline), lower rates of confirmed virological response at 96 weeks to ATV/r or ritonavir-boosted lopinavir (LPV/r) were observed among women compared with men, but no gender difference was apparent in supportive analyses that used a definition of virological response based upon observed cases [ 18 ].

also in 455 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.